secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001437749-23-005220
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotech Q4 net loss $5.6M; FY net income $0; guides FY2023 product rev $205-210M
--------------------------------------------------------------------------------

- Q4 product revenue $53.7M (+5% YoY); full year $200.0M (+6% YoY).
- Q4 GAAP net loss $5.6M ($0.12/sh) vs net income $4.2M in Q4 2021; includes $12.4M legal accrual.
- Full year 2022 GAAP net income $0.0M ($0.00/sh) vs net loss $29.1M in 2021.
- Non-GAAP adjusted net income FY2022 $11.8M ($0.26/sh) vs $3.5M ($0.09/sh) in 2021.
- FY2023 guidance: product revenue $205-210M, royalty rev $25-30M, net income $20-24M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923005220/0001437749-23-005220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923005220/pbyi20230222_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-005220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer